Market closed

Nkarta/$NKTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Nkarta

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Ticker

$NKTX
Trading on

Industry

Biotechnology

Employees

157

Nkarta Metrics

BasicAdvanced
$128M
-
-$1.60
0.90
-
$128M
0.9
$8.33
$1.31
1.9M
14.449
14.133
18.193
19.676
-18.21%
-31.94%
0.31
0.31
-1.18
-33.13%
-15.10%

What the Analysts think about Nkarta

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Nkarta stock.

Nkarta Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Nkarta Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NKTX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs

What’s the current market cap for Nkarta stock?

Nkarta (NKTX) has a market cap of $128M as of April 20, 2025.

What is the P/E ratio for Nkarta stock?

The price to earnings (P/E) ratio for Nkarta (NKTX) stock is 0 as of April 20, 2025.

Does Nkarta stock pay dividends?

No, Nkarta (NKTX) stock does not pay dividends to its shareholders as of April 20, 2025.

When is the next Nkarta dividend payment date?

Nkarta (NKTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Nkarta?

Nkarta (NKTX) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.